STUDY QUESTION What is the impact of male age- and sperm-related factors on embryonic aneuploidy? SUMMARY ANSWER Using a 3-fold analysis framework encompassing patient-level, embryo-level, and matching analysis, we found no clinically significant interactions between male age and sperm quality with embryo ploidy. WHAT IS KNOWN ALREADY While the effect of maternal age on embryo chromosomal aneuploidy is well-established, the impact of male age and sperm quality on ploidy is less well-defined. STUDY DESIGN, SIZE, DURATION This retrospective cohort study analyzed autologous preimplantation genetic testing for aneuploidy (PGT-A) and frozen embryo transfer cycles from December 2014 to June 2021. The study involved 11 087 cycles from 8484 patients, with a total of 35 797 embryos. PARTICIPANTS/MATERIALS, SETTING, METHODS The aneuploidy rate, calculated as the ratio of aneuploid blastocysts to the total number of blastocysts biopsied in a single treatment cycle, was evaluated. In the embryo-level analysis, the main outcome measure was the ploidy state of the embryos. The study employed a multifaceted analytical approach that included a patient-level analysis using generalized linear mixed models, an embryo-level analysis focusing on chromosomal ploidy, and a propensity score matching analysis contrasting groups with distinct ploidy rates (0% and 100%). There were no interventions as this was an observational study of PGT-A cycles. MAIN RESULTS AND THE ROLE OF CHANCE No clinically relevant factors influencing ploidy rate related to male and sperm quality were revealed. In contrast, female age (coefficient = -0.053), BMI (coefficient = 0.003), prior ART cycle (coefficient = -0.066), and number of oocytes retrieved (coefficient = -0.018) were identified at the patient level. Embryo analysis identified age (coefficient = -0.1244) and ICSI usage (coefficient = -0.0129) as significant factors. Despite these, no significant interactions between male and female assessed factors on the ploidy rate emerged. Propensity score matching between maximal (100% vs 0%) euploid rates did not reveal significant differences of influence by male age and sperm quality. LIMITATIONS, REASONS FOR CAUTION The focus on patients having blastocyst biopsy for PGT-A may not reflect the broader IVF population. Other semen quality parameters like DNA fragmentation were not included. Exclusion of embryo mosaicism from the analysis could affect aneuploidy rate interpretations. There may also be unmeasured influences like lifestyle or environmental factors. WIDER IMPLICATIONS OF THE FINDINGS Male age and sperm quality parameters were consistent across both maximal and minimal ploidy rate comparisons. No significant clinical characteristics related to the factors assessed for the male-influenced blastocyst ploidy status, confirming the dominancy of the oocyte and female age. STUDY FUNDING/COMPETING INTEREST(S) The study was not funded. There are no competing interests. TRIAL REGISTRATION NUMBER N/A.

中文翻译：

---

精子因素会影响胚胎非整倍体吗？卵母细胞万岁。


研究问题：男性年龄和精子相关因素对胚胎非整倍体有什么影响？总结答案 使用包括患者水平、胚胎水平和匹配分析在内的 3 重分析框架，我们发现男性年龄和精子质量与胚胎倍性之间没有临床显着的相互作用。已经知道的虽然母体年龄对胚胎染色体非整倍体的影响已得到充分证实，但男性年龄和精子质量对倍性的影响尚不明确。研究设计、规模、持续时间 这项回顾性队列研究分析了 2014 年 12 月至 2021 年 6 月的自体植入前非整倍体基因检测 （PGT-A） 和冷冻胚胎移植周期。该研究涉及来自 8484 名患者的 11 087 个周期，共有 35 797 个胚胎。参与者/材料、设置、方法 评估非整倍体率，计算为非整倍体囊胚与单个治疗周期中活检的囊胚总数的比率。在胚胎水平分析中，主要结局指标是胚胎的倍性状态。该研究采用了多方面的分析方法，包括使用广义线性混合模型的患者水平分析、专注于染色体倍性（染色体倍性）的胚胎水平分析，以及对比具有不同倍性率（0% 和 100%）的组的倾向评分匹配分析。没有干预措施，因为这是一项关于 PGT-A 周期的观察性研究。主要结果和机会的作用 没有揭示影响与男性和精子质量相关的倍性率的临床相关因素。相比之下，女性年龄 （系数 = -0.053） 、 BMI （系数 = 0.003） 、既往 ART 周期 （系数 = -0.066） 和取卵数 （系数 = -0.018） 是在患者水平确定的。 胚胎分析确定年龄 （系数 = -0.1244） 和 ICSI 使用情况 （系数 = -0.0129） 是重要因素。尽管如此，男性和女性评估因素之间没有出现倍性率的显着交互作用。最大 （100% 对 0%） 整倍体率之间的倾向评分匹配未显示男性年龄和精子质量的影响存在显着差异。局限性，谨慎的原因 对接受 PGT-A 囊胚活检的患者的关注可能无法反映更广泛的 IVF 人群。其他精液质量参数，如 DNA 片段化，不包括在内。从分析中排除胚胎嵌合体可能会影响非整倍体率的解释。也可能有无法衡量的影响，例如生活方式或环境因素。研究结果的更广泛意义 男性年龄和精子质量参数在最大倍性率和最小倍性率比较中是一致的。与评估受男性影响的囊胚倍性状态的因素无关的显着临床特征，证实了卵母细胞和女性年龄的优势。研究经费/利益争夺 该研究没有经费。没有相互竞争的利益。试验注册号 N/A。